Petros Pharmaceuticals, Inc. (PTPI)
| Market Cap | 132.08K -84.0% |
| Revenue (ttm) | n/a |
| Net Income | -17.36M |
| EPS | -0.39 |
| Shares Out | 42.37M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 120,002 |
| Open | 0.00325 |
| Previous Close | 0.0031 |
| Day's Range | 0.003117 - 0.00325 |
| 52-Week Range | 0.0017 - 0.0225 |
| Beta | 2.17 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About Petros Pharmaceuticals
Petros Pharmaceuticals, Inc., a healthcare technology company, focuses on developing and licensing proprietary software as a service (SaaS) platform and Software as a medical device web application designed to assist pharmaceutical companies. The company is based in New York, New York. [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
Petros Pharmaceuticals announces deconsolidation of Metuchen subsidiary
Petros Pharmaceuticals (PTPI) announces the strategic deconsolidation of its wholly owned subsidiary, Metuchen Pharmaceuticals, including its wholly owned subsidiaries, Timm Medical Technologies, Inc....
Petros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company's Equity Position
NEW YORK, NY / ACCESS Newswire / June 25, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the c...
Petros Pharmaceuticals announces transition from Nasdaq to OTC Markets
Petros Pharmaceuticals (PTPI) has received a staff determination letter from the Nasdaq Stock Market, informing the Company that Nasdaq determined to suspend trading and delist the Company’s common st...
Petros Pharmaceuticals Announces Transition from NASDAQ to OTC Markets
The Company Intends to Appeal the Delisting Determination NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or the "Company"), a company focused on e...
Petros Pharmaceuticals partners with Innolitics
Petros Pharmaceuticals (PTPI) announces its partnership with Innolitics. The collaboration is intended to integrate many of the Company’s emerging capabilities in the ongoing development of its SaaS p...
Petros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device Developer
With more than $10m in cash, and a significantly reduced burn rate, the Company is positioned to fully fund the development of its technology platform. NEW YORK, NY / ACCESS Newswire / May 20, 2025 / ...
Petros Pharmaceuticals strengthens partnership with big data provider
Petros Pharmaceuticals (PTPI) has implemented multiple enhancements to its developing AI platform, which is expected to improve processing and fraud detection and provide a better overall experience. ...
Petros Pharmaceuticals Strengthens Partnership with Market Leading Big Data Provider Implementing Key Enhancements to its AI Platform
Company continues to innovate and develop its SaaS-based platform to facilitate Rx-to-OTC switch in line with recent President Trump Executive Order NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Petr...
Petros Pharmaceuticals developing SaaS Platform using AI, EHR
Petros Pharmaceuticals (PTPI) announces a concerted effort toward evolving into a smart healthcare technology company through the development of a SaaS platform designed to complement its proprietary ...
Petros Pharmaceuticals Developing First-in-Industry SaaS Platform Utilizing AI and Electronic Health Records Intended to Facilitate Rx-OTC Switches
Licensable platform intended to facilitate industry compliance with President Trump's recent Executive Order to expand access to medicines through OTC approvals under his Make America Healthy Again (M...
Petros Pharmaceuticals trading halted, news pending
19:50 EDT Petros Pharmaceuticals (PTPI) trading halted, news pending
Petros Pharmaceuticals to effect 1-for-25 reverse stock split
The compny intends to effect a reverse stock split of its common stock, par value $0.0001 per share at a ratio of 1 post-split share for every 25 pre-split shares.
Petros highlights Trump executive order on Rx-to-OTC reclassification reforms
Petros Pharmaceuticals (PTPI) highlights President Trump’s April 15, 2025 Executive Order, titled, “Lowering Drug Prices By Once Again Putting Americans First”, as a demonstration that the Company’s r...
Petros Proprietary Technology Platform Aligns with April 15, 2025 President Trump Executive Order Advancing Rx-to-OTC Reclassification Reforms
Company's AI and Big Data technology positioned to drive strong industry collaboration Company also announces certain corporate actions NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Petros Pharmac...
Petros Pharmaceuticals enters collaboration with big data, analytics firm
Petros Pharmaceuticals (PTPI) announces a collaboration with a Big Data and analytics leader to enhance the development of its proprietary technology solutions designed to facilitate Rx-to-OTC switche...
Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple Indications
Company to integrate industry leading big data technology solutions into its AI-driven platform to expand capabilities in identifying eligible patients to receive formerly Rx medications over the coun...
Petros Pharmaceuticals announces top-line results of expanded App Comp study
Petros announces top-line results of its expanded Application Comprehension study, which determines consumer comprehension of its unique messaging within its proprietary Technology. In the study, the ...
Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal Study
Proprietary technology utilizing AI and big data integrations to enable Rx to OTC switch candidates across multiple indications NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Petros Pharmaceutic...
Petros Pharmaceuticals prices 40M shares at 24c in public offering
Petros Pharmaceuticals (PTPI) announces the pricing of a public offering of approximately 40,000,000 shares of the Company’s common stock, par value $0.0001 per share, with each share of Common Stock…
Petros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and Warrants
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-t...
Petros Pharmaceuticals files to sell units, no amount given
Dawson James Securities is exclusive placement agent.
Petros announces ‘conducive position’ with newly approved FDA OTC final rules
Petros Pharmaceuticals (PTPI) announces its conducive position in connection with the recently issued final rule, “Nonprescription Drug Product with an Additional Condition for Nonprescription Use” by...
Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final Rules
Proprietary technology developing quantum computing and applying AI to better enable Rx to OTC switch candidates across multiple indications NEW YORK, NY / ACCESSWIRE / January 7, 2025 / Petros Pharma...
Petros Pharmaceuticals Featured in “New Era of Healthcare, AI, Data and Consumer Empowerment”
Company positions itself for new innovation utilizing AI and quantum computing to help expand patient access to drugs via OTC access NEW YORK, NY / ACCESSWIRE / December 19, 2024 / Petros Pharmaceutic...
Petros to shift focus to development of tech as Rx-to-OTC switch solution
Petros Pharmaceuticals (PTPI) announces a shift in its corporate strategy to focus on the development of its proprietary technology platform as a prospective Rx-to-OTC switch solution across a multitu...